The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-β-mediated growth regulation

Journal of Pathology

Volumn 219, Issue 2, 2009, Pages 263-274

  Ponnamperuma, Roshini M ^a   King, Kathryn E ^a   Elsir, Tamador ^b   Glick, Adam B ^c   Wahl, Geoffrey M ^d   Nister, Monica ^b   Weinberg, Wendy C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Epidermis; p53; Senescence; Squamous cell carcinoma; TGF ; Transactivation; Tumour suppression

Indexed keywords

AMINO ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; PROTEIN P53; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VALINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BENIGN TUMOR; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DISSOCIATION; DNA BINDING; EPITHELIUM; FIBROBLAST; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SENESCENCE; SKIN CARCINOGENESIS; SKIN TUMOR; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENES, P53; GENOTYPE; KERATINOCYTES; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349144132     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2600     Document Type: Article

References (42)

1. Wang W, Rastinejad F, El Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther 2003;2:S55-S63.
2. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006;6:55-61.
3. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med 2002;8:282-288. (Pubitemid 34250107)
4. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848. (Pubitemid 38174664)
5. Guimaraes DP, Hainaut P. TP53: a key gene in human cancer. Biochimie 2002;84:83-93. (Pubitemid 34477096)
6. You H, Yamamoto K, Mak TW. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci U S A 2006;103:9051-9056. (Pubitemid 43902531)
7. Chylicki K, Ehinger M, Svedberg H, Gullberg U. Characterization of the molecular mechanisms for p53-mediated differentiation. Cell Growth Differ 2000;11:561-571. (Pubitemid 30841264)
8. Bertrand P, Saintigny Y, Lopez BS. p53's double life: transactivation-independent repression of homologous recombination. Trends Genet 2004;20:235-243. (Pubitemid 38625681)
9. Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 2003;63:2596-2605. (Pubitemid 36605201)
10. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577-590. (Pubitemid 36385115)
11. Dumont P, Leu JI, Della PA III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet 2003;33:357-365. (Pubitemid 36278852)
12. Weinberg WC, Azzoli CG, Kadiwar N, Yuspa SH. p53 gene dosage modifies growth and malignant progression of keratinocytes expressing the v-rasHa oncogene. Cancer Res 1994;54:5584-5592. (Pubitemid 24980100)
13. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993;74:813-822. (Pubitemid 23270601)
14. Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, et al. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nature Genet 2000;26:37-43. (Pubitemid 30692853)
15. Nister M, Tang M, Zhang XQ, Yin C, Beeche M, Hu X, et al. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene 2005;24:3563-3573. (Pubitemid 40756226)
16. Tang M, Wahl GM, Nister M. Explaining the biological activity of transactivation-deficient p53 variants. Nature Genet 2006;38:395-396.
17. Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 2000;19:4967-4975. (Pubitemid 30727353)
18. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
19. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 1995;10:2271-2279.
20. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-830.
21. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 2003;113:301-314. (Pubitemid 36556113)
22. Azzoli CG, Sagar M, Wu A, Lowry D, Hennings H, Morgan DL, et al. Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines. Mol Carcinog 1998;21:50-61. (Pubitemid 28097950)
23. Tremain R, Marko M, Kinnimulki V, Ueno H, Bottinger E, Glick A. Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene 2000;19:1698-1709. (Pubitemid 30200972)
24. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-9367.
25. King KE, Ponnamperuma RM, Yamashita T, Tokino T, Lee LA, Young MF, et al. ΔNp63a functions as a positive and negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene 2003;22:3635-3644. (Pubitemid 36765323)
26. Roop DR, Lowy DR, Tambourin PE, Strickland J, Harper JR, Balaschak M, et al. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 1986;323:822-824.
27. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006;66:2881-2884.
28. Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol 2005;17:49-54.
29. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994;8:2429-2440. (Pubitemid 2163270)
30. Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, et al. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Mol Cell Biol 2007;27:8228-8242. (Pubitemid 350234236)
31. Weinberg WC, Montano NE, Deng C. Loss of p21CIP1/WAF1 does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis. Oncogene 1997;15:685-690. (Pubitemid 27389931)
32. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 1991;5:151-159. (Pubitemid 21905941)
33. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-680. (Pubitemid 20275708)
34. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
35. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet 1995;9:305-311.
36. Martinez JD, Craven MT, Joseloff E, Milczarek G, Bowden GT. Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation. Oncogene 1997;14:2511-2520. (Pubitemid 27273513)
37. Johnson TM, Attardi LD. Reply to explaining the biological activity of transactivation-deficient p53 variants. Nature Genet 2006;38:396-397.
38. Johnson TM, Hammond EM, Giaccia A, Attardi LD. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nature Genet 2005;37:145-152.
39. Zhu J, Zhou W, Jiang J, Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 1998;273:13030-13036. (Pubitemid 28246867)
40. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, et al. Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science 2007;315:840-843. (Pubitemid 46255835)
41. Zhu J, Jiang J, Zhou W, Zhu K, Chen X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 1999;18:2149-2155. (Pubitemid 29178584)
42. Johnson TM, Meade K, Pathak N, Marques MR, Attardi LD. Knock-in mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci U S A 2008;105:1215-1220.